INS and type 2 diabetes mellitus: This real-world health economic evaluation along with a comprehensive systematic review suggest that the use of a GLP-1RA versus insulin has a high likelihood of being cost-effective for T2D patients who require intensified injection therapy from a third-party payer, healthcare sector, and societal perspectives.